Ocular Therapeutix enrolls first patients in Dextenza phase 3 clinical trial

Ocular Therapeutix Inc. has enrolled the first patients in its third phase 3 clinical trial for Dextenza to treat postoperative ocular inflammation and pain, according to a company release.The prospective, multicenter, parallel-arm, double-masked study will randomize 436 patients undergoing clear corneal cataract surgery to receive either Dextenza (sustained release dexamethasone) 0.4 mg Intracanalicular Depot or placebo vehicle. Primary endpoints are absence of anterior chamber cells at day 14 and reduction of pain at day 8.